Cancer Biomarker Market Growth To $52.63 Billion By 2030: What’s Driving The Expansion?
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cancer Biomarker Market Size And Revenue Outlook Through 2030
The cancer biomarker market has experienced substantial expansion in its size over recent years. This market is projected to expand from $25.09 billion in 2025 to $29.07 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.9%. Historically, this growth can be ascribed to a global increase in cancer cases, progress in molecular biology studies, a rise in funding for oncology research, greater acceptance of diagnostics based on biomarkers, and enhancements in imaging and assay techniques.
The cancer biomarker market is anticipated to experience swift expansion in the upcoming years. This market is projected to reach $52.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.0%. Factors contributing to this growth during the forecast period include a rising demand for tailored oncology treatments, increased investments in precision medicine, the expansion of drug development guided by biomarkers, the growing application of AI-based biomarker analysis, and a heightened emphasis on screening for early-stage cancer. Key trends anticipated over the forecast period involve the expanded utilization of genetic and protein biomarkers, an uptick in the adoption of companion diagnostics, the increasing integration of omics technologies, a broader application of liquid biopsy techniques, and an intensified focus on identifying cancer at early stages.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Biomarker Market Growth Factors Behind Sustained Expansion
The escalating prevalence of cancer is fueling expansion within the cancer biomarker market. The cancer incidence rate refers to the count of new cancer cases, specific to a site or type, observed in a particular population over a year, expressed as the number of cancers per 100,000 at-risk individuals. This growing cancer occurrence leads to the extensive adoption of cancer biomarkers, which are instrumental in evaluating disease risk, screening for hidden primary tumors, distinguishing between benign and malignant indicators, or differentiating various forms of malignancy. Cancer biomarkers facilitate early identification, diagnosis, and ongoing monitoring of the disease by signaling its presence or advancement, thereby enabling tailored treatment approaches and enhancing patient results. As an illustration, a report released in May 2024 by the International Agency for Research on Cancer (IARC), a cancer research body based in France, indicated that in 2022, approximately 20 million new cancer cases were documented, leading to 9.7 million deaths. Projections suggest that by 2050, new cancer cases will exceed 35 million, marking a 77% rise from 2022. Consequently, the escalating incidence of cancer is anticipated to drive forward the growth of the cancer biomarker market in the years ahead.
Cancer Biomarker Market Segment Analysis And Revenue Potential
The cancer biomarker market covered in this report is segmented –
1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein
2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles
3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers
Cancer Biomarker Market Industry Trends Fueling Future Revenue Growth
Leading firms within the cancer biomarker market are concentrating their efforts on creating advanced solutions, including AI-powered cancer biomarkers, aimed at improving the precision of diagnoses and tailoring therapeutic strategies for individuals. These AI-powered cancer biomarkers are defined as biological markers of the disease whose detection and examination rely on artificial intelligence technologies. As an illustration, in September 2023, Ibex Medical Analytics, a US-based Ibex Medical Analytics, introduced Galen Breast HER2, an AI-driven solution developed to boost the accuracy and consistency of HER2 scoring for individuals with breast cancer. This cutting-edge platform assists pathologists by automatically identifying invasive tumor regions and measuring HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs a new computational process to scrutinize immunohistochemistry (IHC)-stained slides, offering comprehensive visual representations of staining patterns and empowering pathologists to render well-grounded treatment choices.
Cancer Biomarker Market Leading Players And Competitive Positioning
Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.
View The Full Cancer Biomarker Market Report:
Cancer Biomarker Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
